Natural Products as Lead Molecules in Innovative Drug Discovery: A Comprehensive Review of High-Throughput Screening, Structural Optimization, and Therapeutic Horizons

Abstract

Natural products derived from terrestrial plants, marine organisms, andmicroorganisms have historically served as the bedrock of pharmacotherapy,yielding pivotal therapeutic agents such as aspirin, penicillin, and paclitaxel.Despite the rise of synthetic combinatorial chemistry and high-throughputscreening of synthetic libraries during the late 20th century, the chemicaldiversity and biological relevance of natural scaffolds remain unmatched. This review paper provides a rigorous, multi-faceted analysis of natural products as lead molecules in modern innovative drug discovery pipelines. We examine the transition from traditional bioassay-guided isolation to advanced multi-dimensional screening platforms, highlighting the synergy between artificial intelligence (AI), machine learning (ML), high-resolution mass spectrometry (HR-MS), and nuclear magnetic resonance (NMR) spectroscopy. The fundamental challenges of natural product-based drug discovery—specifically, the structural complexity of lead isolates, low extraction yields, supply chain instabilities, and the frequent rediscovery of known entities (dereplication)—are thoroughly interrogated. We critically review contemporary structural optimization strategies, including semi-synthetic modifications, total synthesis, and biosynthetic gene cluster (BGC)engineering, which allow researchers to circumvent formulation challengesand scale up production. Furthermore, this paper documents the strategicdeployment of natural product leads across key therapeutic domains,including oncology, antimicrobial resistance (AMR), neurodegenerativedisorders, and metabolic syndromes. By examining quantitative screeningefficiency metrics, hit-to-lead success rates, and clinical transition pipelinesover the past two decades, this review addresses a critical research gap: thelack of holistic frameworks integrating computational genomics, automation,and synthetic biology with natural product pharmacology. Finally, weformulate actionable methodologies and future research roadmaps,demonstrating that the structural evolution of natural product scaffoldsremains an indispensable engine for addressing unmet clinical needs andshaping the next generation of precision medicine.  KEYWORDS: Natural Products; Lead Optimization; Drug Discovery;Biosynthetic Gene Clusters; High-Throughput Screening; Chemoinformatics;Secondary Metabolites; Structural Complexity.